1. Home
  2. AISP vs AGEN Comparison

AISP vs AGEN Comparison

Compare AISP & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Airship AI Holdings Inc.

AISP

Airship AI Holdings Inc.

HOLD

Current Price

$2.70

Market Cap

112.1M

Sector

Finance

ML Signal

HOLD

Logo Agenus Inc.

AGEN

Agenus Inc.

HOLD

Current Price

$3.28

Market Cap

126.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AISP
AGEN
Founded
2006
1994
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
112.1M
126.2M
IPO Year
N/A
1999

Fundamental Metrics

Financial Performance
Metric
AISP
AGEN
Price
$2.70
$3.28
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$14.50
AVG Volume (30 Days)
581.7K
410.2K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.37
Revenue
N/A
$42,877,086.00
Revenue This Year
$222.88
$5.19
Revenue Next Year
$5.36
$68.25
P/E Ratio
$3.18
$9.12
Revenue Growth
N/A
89.95
52 Week Low
$2.36
$1.38
52 Week High
$7.20
$7.34

Technical Indicators

Market Signals
Indicator
AISP
AGEN
Relative Strength Index (RSI) 45.96 53.30
Support Level $2.36 $2.90
Resistance Level $3.92 $4.72
Average True Range (ATR) 0.18 0.18
MACD 0.05 0.06
Stochastic Oscillator 53.28 83.87

Price Performance

Historical Comparison
AISP
AGEN

About AISP Airship AI Holdings Inc.

Airship AI Holdings Inc is a robust AI-driven data management platform that solves complex data challenges for large institutions operating in dynamic and mission-critical environments with rapidly increasing volumes of data being ingested from a similarly rapidly growing number of data sources. Its primary offerings include Outpost AI, Acropolis, and Airship Command. Its offerings allow customers to manage their data across the full data lifecycle, when and where need it, using a secure permission-based architecture.

About AGEN Agenus Inc.

Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Share on Social Networks: